Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24141203 | 1.00 | QDPR (0.56) | QDPRTLR7TLR8TLR9PRMT5 | |
| SCHEMBL24140563 | 0.88 | QDPR (0.53) | QDPRTLR7TLR8TLR9PRMT5 | |
| SCHEMBL24140543 | 0.86 | AMY1A (0.49) | PDE4BAMY1A | |
| SCHEMBL24141227 | 0.85 | AMY1A (0.48) | PDE4BAMY1A | |
| SCHEMBL30472012 | 0.84 | AMY1A (0.47) | QDPRTLR7TLR8TLR9AMY1A | |
| SCHEMBL25316441 | 0.84 | AMY1A (0.47) | QDPRTLR7TLR8TLR9AMY1A | |
| SCHEMBL24140751 | 0.83 | ALDH1A1 (0.52) | AMY1ACHEK2 | |
| SCHEMBL24140523 | 0.79 | KDM4E (0.47) | TLR7TLR8AMY1AHTR2B | |
| SCHEMBL30472059 | 0.79 | KDM4E (0.47) | TLR7TLR8AMY1AHTR2B | |
| SCHEMBL25311414 | 0.78 | AMY1A (0.46) | PDE4BAMY1ACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | QDPR 2656/4885TLR7 844/4885TLR8 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.